| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Tract Infections | 62 | 2024 | 295 | 14.550 |
Why?
|
| Bacteriuria | 35 | 2024 | 82 | 12.410 |
Why?
|
| Catheter-Related Infections | 30 | 2024 | 131 | 8.500 |
Why?
|
| Antimicrobial Stewardship | 18 | 2024 | 84 | 6.460 |
Why?
|
| Anti-Bacterial Agents | 57 | 2024 | 2398 | 6.330 |
Why?
|
| Urinary Catheterization | 25 | 2024 | 81 | 5.220 |
Why?
|
| Urinary Catheters | 14 | 2024 | 24 | 3.830 |
Why?
|
| Cystitis | 7 | 2023 | 50 | 3.500 |
Why?
|
| Spinal Cord Injuries | 12 | 2023 | 310 | 3.470 |
Why?
|
| Inappropriate Prescribing | 6 | 2019 | 41 | 2.630 |
Why?
|
| Catheters, Indwelling | 15 | 2020 | 155 | 2.540 |
Why?
|
| Urinalysis | 10 | 2022 | 61 | 2.270 |
Why?
|
| Asymptomatic Infections | 9 | 2019 | 33 | 2.220 |
Why?
|
| Cross Infection | 11 | 2020 | 330 | 2.190 |
Why?
|
| Anti-Infective Agents | 7 | 2023 | 266 | 2.000 |
Why?
|
| Escherichia coli | 17 | 2024 | 983 | 1.910 |
Why?
|
| Health Knowledge, Attitudes, Practice | 9 | 2024 | 827 | 1.870 |
Why?
|
| Hospitals, Veterans | 7 | 2019 | 354 | 1.660 |
Why?
|
| Nursing Homes | 10 | 2021 | 95 | 1.660 |
Why?
|
| Bacteremia | 7 | 2018 | 405 | 1.610 |
Why?
|
| Fluoroquinolones | 7 | 2024 | 92 | 1.590 |
Why?
|
| Humans | 156 | 2025 | 123259 | 1.510 |
Why?
|
| Antibiosis | 5 | 2017 | 13 | 1.450 |
Why?
|
| Escherichia coli Infections | 8 | 2023 | 190 | 1.390 |
Why?
|
| Urine | 9 | 2021 | 89 | 1.360 |
Why?
|
| Veterans | 11 | 2023 | 1737 | 1.320 |
Why?
|
| Enterobacteriaceae | 3 | 2018 | 35 | 1.320 |
Why?
|
| Bacterial Adhesion | 5 | 2012 | 107 | 1.310 |
Why?
|
| Biofilms | 6 | 2012 | 91 | 1.300 |
Why?
|
| Drug Utilization | 4 | 2020 | 159 | 1.270 |
Why?
|
| Unnecessary Procedures | 4 | 2019 | 56 | 1.230 |
Why?
|
| Infection Control | 10 | 2024 | 160 | 1.200 |
Why?
|
| Gram-Negative Bacterial Infections | 4 | 2022 | 86 | 1.170 |
Why?
|
| Nonprescription Drugs | 2 | 2019 | 46 | 1.160 |
Why?
|
| Outpatients | 6 | 2024 | 254 | 1.140 |
Why?
|
| Attitude of Health Personnel | 5 | 2020 | 643 | 1.140 |
Why?
|
| Catheters | 5 | 2023 | 89 | 1.130 |
Why?
|
| Physicians | 5 | 2024 | 581 | 1.090 |
Why?
|
| Phage Therapy | 4 | 2023 | 24 | 1.060 |
Why?
|
| Bacteriophages | 6 | 2023 | 77 | 1.010 |
Why?
|
| Medical Audit | 3 | 2018 | 99 | 1.000 |
Why?
|
| Prostatitis | 2 | 2023 | 13 | 1.000 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2024 | 714 | 0.980 |
Why?
|
| Diagnostic Errors | 4 | 2016 | 327 | 0.870 |
Why?
|
| Natural Language Processing | 4 | 2016 | 63 | 0.860 |
Why?
|
| Catheterization, Peripheral | 3 | 2020 | 126 | 0.860 |
Why?
|
| United States | 26 | 2023 | 10652 | 0.860 |
Why?
|
| Internship and Residency | 4 | 2022 | 1160 | 0.860 |
Why?
|
| Aged | 36 | 2025 | 19195 | 0.850 |
Why?
|
| Female | 64 | 2025 | 65615 | 0.850 |
Why?
|
| Drug Resistance, Bacterial | 7 | 2023 | 361 | 0.810 |
Why?
|
| Electronic Health Records | 5 | 2016 | 713 | 0.800 |
Why?
|
| Health Personnel | 3 | 2017 | 492 | 0.790 |
Why?
|
| Middle Aged | 38 | 2025 | 26087 | 0.790 |
Why?
|
| Pyelonephritis | 1 | 2022 | 26 | 0.780 |
Why?
|
| Pyuria | 1 | 2021 | 6 | 0.750 |
Why?
|
| Male | 57 | 2025 | 60333 | 0.740 |
Why?
|
| Prosthesis-Related Infections | 2 | 2021 | 177 | 0.740 |
Why?
|
| Adult | 41 | 2025 | 29098 | 0.740 |
Why?
|
| Hospitalization | 6 | 2024 | 1737 | 0.730 |
Why?
|
| Guideline Adherence | 5 | 2017 | 373 | 0.710 |
Why?
|
| Inpatients | 4 | 2018 | 493 | 0.690 |
Why?
|
| Evidence-Based Medicine | 4 | 2017 | 623 | 0.680 |
Why?
|
| Medicine | 1 | 2021 | 96 | 0.680 |
Why?
|
| Enterococcus faecalis | 3 | 2011 | 45 | 0.660 |
Why?
|
| Treatment Failure | 3 | 2019 | 335 | 0.660 |
Why?
|
| Practice Patterns, Nurses' | 1 | 2019 | 8 | 0.660 |
Why?
|
| Self Medication | 1 | 2019 | 23 | 0.660 |
Why?
|
| Aged, 80 and over | 13 | 2020 | 6392 | 0.650 |
Why?
|
| Drug Resistance, Microbial | 3 | 2021 | 192 | 0.650 |
Why?
|
| Enterobacteriaceae Infections | 2 | 2018 | 55 | 0.640 |
Why?
|
| Algorithms | 3 | 2017 | 1598 | 0.620 |
Why?
|
| Nitrofurantoin | 2 | 2023 | 9 | 0.610 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 1253 | 0.600 |
Why?
|
| General Surgery | 1 | 2020 | 203 | 0.590 |
Why?
|
| Surveys and Questionnaires | 13 | 2024 | 3676 | 0.580 |
Why?
|
| Oncologists | 1 | 2018 | 29 | 0.580 |
Why?
|
| Hospitals | 7 | 2023 | 392 | 0.580 |
Why?
|
| Length of Stay | 3 | 2018 | 1290 | 0.570 |
Why?
|
| Osteomyelitis | 2 | 2019 | 204 | 0.570 |
Why?
|
| Physicians, Women | 1 | 2018 | 45 | 0.570 |
Why?
|
| Disease Notification | 1 | 2017 | 7 | 0.570 |
Why?
|
| Hospitalists | 1 | 2018 | 45 | 0.560 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 421 | 0.560 |
Why?
|
| Epidemiological Monitoring | 1 | 2017 | 59 | 0.550 |
Why?
|
| Primary Health Care | 7 | 2024 | 754 | 0.550 |
Why?
|
| Patients | 1 | 2018 | 121 | 0.550 |
Why?
|
| Enterococcus | 3 | 2019 | 32 | 0.540 |
Why?
|
| Mass Screening | 2 | 2019 | 787 | 0.540 |
Why?
|
| Retrospective Studies | 19 | 2023 | 16068 | 0.540 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2017 | 141 | 0.530 |
Why?
|
| Long-Term Care | 5 | 2021 | 70 | 0.530 |
Why?
|
| Medical Overuse | 1 | 2016 | 27 | 0.530 |
Why?
|
| Attitude to Health | 1 | 2018 | 260 | 0.520 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 5 | 2024 | 42 | 0.520 |
Why?
|
| Formative Feedback | 1 | 2016 | 31 | 0.520 |
Why?
|
| United States Department of Veterans Affairs | 4 | 2018 | 659 | 0.520 |
Why?
|
| Prevalence | 10 | 2022 | 2409 | 0.520 |
Why?
|
| Documentation | 2 | 2016 | 120 | 0.520 |
Why?
|
| Bacterial Infections | 3 | 2023 | 305 | 0.510 |
Why?
|
| Lactobacillus | 2 | 2014 | 43 | 0.510 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 2478 | 0.510 |
Why?
|
| Clinical Competence | 5 | 2014 | 972 | 0.500 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2017 | 166 | 0.490 |
Why?
|
| Urinary Bladder | 2 | 2022 | 242 | 0.490 |
Why?
|
| Ciprofloxacin | 4 | 2024 | 66 | 0.490 |
Why?
|
| Biodiversity | 1 | 2015 | 64 | 0.480 |
Why?
|
| Chronic Disease | 2 | 2023 | 1168 | 0.480 |
Why?
|
| Prospective Studies | 12 | 2021 | 6030 | 0.480 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 59 | 0.470 |
Why?
|
| Extraintestinal Pathogenic Escherichia coli | 3 | 2021 | 24 | 0.460 |
Why?
|
| Models, Theoretical | 1 | 2016 | 356 | 0.450 |
Why?
|
| Diabetes Mellitus | 2 | 2024 | 850 | 0.440 |
Why?
|
| Decision Support Systems, Clinical | 4 | 2020 | 170 | 0.430 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2020 | 164 | 0.430 |
Why?
|
| Medication Therapy Management | 1 | 2013 | 25 | 0.420 |
Why?
|
| Heart-Assist Devices | 1 | 2021 | 1026 | 0.410 |
Why?
|
| Pseudomonas Phages | 1 | 2012 | 10 | 0.410 |
Why?
|
| Fimbriae, Bacterial | 2 | 2011 | 41 | 0.410 |
Why?
|
| Feedback | 3 | 2021 | 162 | 0.400 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2011 | 6 | 0.390 |
Why?
|
| Thrombelastography | 3 | 2021 | 55 | 0.390 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 4 | 2022 | 133 | 0.390 |
Why?
|
| Diabetic Foot | 3 | 2020 | 156 | 0.390 |
Why?
|
| Microbial Sensitivity Tests | 7 | 2024 | 782 | 0.390 |
Why?
|
| Health Services Research | 2 | 2020 | 187 | 0.380 |
Why?
|
| Microbiota | 2 | 2021 | 391 | 0.380 |
Why?
|
| Nanostructures | 1 | 2011 | 52 | 0.380 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 110 | 0.370 |
Why?
|
| Endocarditis | 1 | 2012 | 101 | 0.370 |
Why?
|
| Nitrofurazone | 1 | 2010 | 1 | 0.370 |
Why?
|
| Prostheses and Implants | 1 | 2012 | 150 | 0.370 |
Why?
|
| Silver | 1 | 2010 | 22 | 0.360 |
Why?
|
| Patient Education as Topic | 5 | 2020 | 442 | 0.360 |
Why?
|
| Urology | 1 | 2011 | 75 | 0.360 |
Why?
|
| Rhodobacteraceae | 1 | 2010 | 1 | 0.360 |
Why?
|
| Risk Factors | 10 | 2024 | 10035 | 0.350 |
Why?
|
| Abdomen | 2 | 2021 | 129 | 0.340 |
Why?
|
| Urinary Bladder, Neurogenic | 2 | 2009 | 45 | 0.340 |
Why?
|
| Uropathogenic Escherichia coli | 2 | 2022 | 26 | 0.340 |
Why?
|
| Medication Errors | 1 | 2011 | 184 | 0.330 |
Why?
|
| Microbial Viability | 3 | 2021 | 42 | 0.330 |
Why?
|
| Clostridium Infections | 1 | 2013 | 241 | 0.320 |
Why?
|
| Blood | 4 | 2021 | 105 | 0.320 |
Why?
|
| Efficiency | 2 | 2020 | 58 | 0.320 |
Why?
|
| Endocarditis, Bacterial | 1 | 2010 | 129 | 0.320 |
Why?
|
| Biomedical Research | 1 | 2015 | 517 | 0.320 |
Why?
|
| Heart Failure | 1 | 2021 | 2131 | 0.310 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2020 | 117 | 0.300 |
Why?
|
| Risk Assessment | 5 | 2018 | 3336 | 0.290 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2013 | 266 | 0.290 |
Why?
|
| Texas | 9 | 2024 | 3557 | 0.290 |
Why?
|
| Central Venous Catheters | 2 | 2020 | 38 | 0.290 |
Why?
|
| Proteus | 1 | 2006 | 7 | 0.280 |
Why?
|
| Proteus Infections | 1 | 2006 | 7 | 0.280 |
Why?
|
| Bacteriological Techniques | 3 | 2019 | 87 | 0.280 |
Why?
|
| Urinary Calculi | 1 | 2006 | 18 | 0.280 |
Why?
|
| Aortic Valve | 1 | 2010 | 437 | 0.280 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2007 | 33 | 0.280 |
Why?
|
| Paresis | 1 | 2007 | 36 | 0.270 |
Why?
|
| Catheterization | 2 | 2008 | 237 | 0.270 |
Why?
|
| Staphylococcus aureus | 4 | 2021 | 455 | 0.270 |
Why?
|
| Skin Tests | 1 | 2007 | 74 | 0.270 |
Why?
|
| Functional Laterality | 1 | 2007 | 181 | 0.260 |
Why?
|
| Fever | 2 | 2021 | 296 | 0.260 |
Why?
|
| Chlorhexidine | 2 | 2004 | 45 | 0.250 |
Why?
|
| Internal Medicine | 3 | 2017 | 147 | 0.250 |
Why?
|
| Colicins | 1 | 2005 | 4 | 0.250 |
Why?
|
| Escherichia coli K12 | 1 | 2005 | 3 | 0.250 |
Why?
|
| Cohort Studies | 4 | 2018 | 4701 | 0.250 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2004 | 69 | 0.250 |
Why?
|
| Surgeons | 2 | 2020 | 249 | 0.240 |
Why?
|
| Disease Management | 2 | 2019 | 515 | 0.240 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 3383 | 0.240 |
Why?
|
| Patient Discharge | 2 | 2021 | 492 | 0.240 |
Why?
|
| Point-of-Care Testing | 1 | 2025 | 27 | 0.240 |
Why?
|
| Decision Support Techniques | 2 | 2021 | 280 | 0.240 |
Why?
|
| Antibodies, Viral | 3 | 2025 | 1139 | 0.230 |
Why?
|
| Gammaproteobacteria | 1 | 2024 | 16 | 0.230 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 605 | 0.220 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 1878 | 0.220 |
Why?
|
| Recurrence | 3 | 2019 | 1418 | 0.220 |
Why?
|
| Spinal Cord Diseases | 1 | 2023 | 40 | 0.220 |
Why?
|
| Prescriptions | 1 | 2023 | 40 | 0.220 |
Why?
|
| 2-Propanol | 1 | 2002 | 3 | 0.200 |
Why?
|
| Point-of-Care Systems | 1 | 2025 | 170 | 0.200 |
Why?
|
| Antisepsis | 1 | 2002 | 9 | 0.200 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 2844 | 0.200 |
Why?
|
| Insurance, Health | 1 | 2023 | 136 | 0.200 |
Why?
|
| Iodine | 1 | 2002 | 24 | 0.200 |
Why?
|
| Interleukin-6 | 1 | 2024 | 395 | 0.200 |
Why?
|
| Blood Specimen Collection | 1 | 2002 | 47 | 0.200 |
Why?
|
| Pericarditis, Tuberculous | 1 | 2001 | 1 | 0.190 |
Why?
|
| Bacteria | 4 | 2023 | 483 | 0.190 |
Why?
|
| Gram-Negative Bacteria | 1 | 2022 | 67 | 0.190 |
Why?
|
| Critical Illness | 3 | 2021 | 591 | 0.190 |
Why?
|
| Postoperative Period | 2 | 2021 | 333 | 0.190 |
Why?
|
| Return to Work | 1 | 2021 | 12 | 0.190 |
Why?
|
| Language | 1 | 2023 | 202 | 0.190 |
Why?
|
| Health Literacy | 2 | 2024 | 80 | 0.190 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2015 | 374 | 0.190 |
Why?
|
| Viral Tail Proteins | 1 | 2021 | 7 | 0.180 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2021 | 17 | 0.180 |
Why?
|
| Microbial Interactions | 1 | 2021 | 16 | 0.180 |
Why?
|
| Career Choice | 1 | 2022 | 142 | 0.180 |
Why?
|
| Ambulatory Care | 1 | 2024 | 378 | 0.180 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2001 | 137 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2023 | 161 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2002 | 232 | 0.180 |
Why?
|
| Quality Improvement | 2 | 2016 | 624 | 0.180 |
Why?
|
| Guidelines as Topic | 2 | 2019 | 197 | 0.170 |
Why?
|
| Polysaccharides | 1 | 2021 | 143 | 0.170 |
Why?
|
| Thrombophilia | 1 | 2020 | 41 | 0.170 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 250 | 0.170 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 84 | 0.170 |
Why?
|
| Emergency Service, Hospital | 3 | 2024 | 1078 | 0.170 |
Why?
|
| Residence Characteristics | 1 | 2022 | 268 | 0.170 |
Why?
|
| Influenza Vaccines | 1 | 2004 | 473 | 0.170 |
Why?
|
| Sepsis | 1 | 2004 | 476 | 0.170 |
Why?
|
| Female Urogenital Diseases | 1 | 2019 | 7 | 0.160 |
Why?
|
| Male Urogenital Diseases | 1 | 2019 | 12 | 0.160 |
Why?
|
| Skin | 1 | 2002 | 507 | 0.160 |
Why?
|
| Workflow | 1 | 2019 | 114 | 0.160 |
Why?
|
| Thoracic Surgery | 1 | 2021 | 157 | 0.160 |
Why?
|
| Data Mining | 2 | 2016 | 54 | 0.160 |
Why?
|
| Recovery of Function | 1 | 2021 | 437 | 0.160 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 123 | 0.160 |
Why?
|
| Antiviral Agents | 1 | 2024 | 744 | 0.160 |
Why?
|
| Activities of Daily Living | 1 | 2021 | 404 | 0.160 |
Why?
|
| Stroke | 1 | 2007 | 958 | 0.160 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 212 | 0.160 |
Why?
|
| Time Factors | 4 | 2020 | 6223 | 0.160 |
Why?
|
| Urination Disorders | 1 | 2018 | 18 | 0.160 |
Why?
|
| Employee Performance Appraisal | 1 | 2018 | 12 | 0.150 |
Why?
|
| Relative Value Scales | 1 | 2018 | 12 | 0.150 |
Why?
|
| Case-Control Studies | 3 | 2025 | 3239 | 0.150 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2018 | 28 | 0.150 |
Why?
|
| Safety Management | 1 | 2019 | 111 | 0.150 |
Why?
|
| Medication Adherence | 2 | 2013 | 389 | 0.150 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2013 | 117 | 0.150 |
Why?
|
| Coliphages | 1 | 2018 | 6 | 0.150 |
Why?
|
| Bacteriolysis | 1 | 2018 | 8 | 0.150 |
Why?
|
| Diagnosis-Related Groups | 1 | 2018 | 28 | 0.150 |
Why?
|
| Patient Participation | 1 | 2020 | 220 | 0.150 |
Why?
|
| Siderophores | 1 | 2017 | 10 | 0.150 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 223 | 0.150 |
Why?
|
| DNA, Bacterial | 2 | 2010 | 474 | 0.140 |
Why?
|
| Patient Satisfaction | 2 | 2020 | 477 | 0.140 |
Why?
|
| Minocycline | 2 | 2008 | 36 | 0.140 |
Why?
|
| Biopsy | 2 | 2019 | 1236 | 0.140 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2001 | 373 | 0.140 |
Why?
|
| Gastric Mucosa | 1 | 2021 | 485 | 0.140 |
Why?
|
| Aortic Rupture | 1 | 2019 | 118 | 0.140 |
Why?
|
| Metals | 1 | 2018 | 62 | 0.140 |
Why?
|
| Homes for the Aged | 1 | 2017 | 24 | 0.140 |
Why?
|
| Audiovisual Aids | 1 | 2017 | 25 | 0.140 |
Why?
|
| Acetylcysteine | 2 | 2008 | 73 | 0.140 |
Why?
|
| Propensity Score | 1 | 2018 | 212 | 0.140 |
Why?
|
| Research | 1 | 2019 | 263 | 0.140 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2016 | 8 | 0.140 |
Why?
|
| Bone and Bones | 1 | 2019 | 263 | 0.140 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2017 | 83 | 0.140 |
Why?
|
| Health Care Surveys | 1 | 2018 | 284 | 0.140 |
Why?
|
| Acute Disease | 2 | 2017 | 1093 | 0.140 |
Why?
|
| Colony Count, Microbial | 2 | 2009 | 89 | 0.130 |
Why?
|
| Goals | 1 | 2017 | 128 | 0.130 |
Why?
|
| Americas | 1 | 2016 | 50 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2019 | 1171 | 0.130 |
Why?
|
| Motivation | 1 | 2018 | 314 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2018 | 243 | 0.130 |
Why?
|
| Secondary Prevention | 1 | 2017 | 212 | 0.130 |
Why?
|
| Linear Models | 1 | 2018 | 669 | 0.130 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 1414 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2019 | 366 | 0.130 |
Why?
|
| Data Collection | 3 | 2013 | 383 | 0.130 |
Why?
|
| Leg | 1 | 2016 | 155 | 0.120 |
Why?
|
| Professional Competence | 1 | 2016 | 97 | 0.120 |
Why?
|
| Faculty, Medical | 1 | 2018 | 260 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 503 | 0.120 |
Why?
|
| Veterans Health | 1 | 2017 | 174 | 0.120 |
Why?
|
| Program Development | 1 | 2016 | 187 | 0.120 |
Why?
|
| Utilization Review | 1 | 2015 | 38 | 0.120 |
Why?
|
| Mannose | 2 | 2011 | 19 | 0.120 |
Why?
|
| Caregivers | 1 | 2020 | 571 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2019 | 546 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2008 | 586 | 0.120 |
Why?
|
| Surface Properties | 2 | 2011 | 76 | 0.120 |
Why?
|
| Curriculum | 1 | 2020 | 714 | 0.120 |
Why?
|
| Young Adult | 4 | 2024 | 8867 | 0.120 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 218 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 357 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 373 | 0.120 |
Why?
|
| Pregnancy | 5 | 2024 | 7129 | 0.120 |
Why?
|
| Adaptation, Psychological | 1 | 2018 | 459 | 0.120 |
Why?
|
| Corynebacterium | 1 | 2014 | 9 | 0.120 |
Why?
|
| Quality of Health Care | 1 | 2017 | 389 | 0.120 |
Why?
|
| Social Norms | 1 | 2014 | 6 | 0.110 |
Why?
|
| Staphylococcus | 1 | 2014 | 70 | 0.110 |
Why?
|
| Reference Standards | 1 | 2015 | 239 | 0.110 |
Why?
|
| Double-Blind Method | 3 | 2022 | 1601 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2017 | 528 | 0.110 |
Why?
|
| Candida | 1 | 2014 | 75 | 0.110 |
Why?
|
| Adolescent | 4 | 2019 | 19127 | 0.110 |
Why?
|
| Intermittent Urethral Catheterization | 1 | 2013 | 8 | 0.110 |
Why?
|
| Withholding Treatment | 1 | 2013 | 67 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2022 | 12169 | 0.110 |
Why?
|
| Pilot Projects | 3 | 2021 | 1389 | 0.110 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 160 | 0.110 |
Why?
|
| Educational Status | 1 | 2014 | 270 | 0.100 |
Why?
|
| Self Efficacy | 1 | 2014 | 192 | 0.100 |
Why?
|
| Quality of Life | 2 | 2021 | 1933 | 0.100 |
Why?
|
| Qualitative Research | 3 | 2020 | 527 | 0.100 |
Why?
|
| Peripheral Arterial Disease | 1 | 2016 | 275 | 0.100 |
Why?
|
| Neutropenia | 3 | 2019 | 202 | 0.100 |
Why?
|
| Photoelectron Spectroscopy | 1 | 2011 | 4 | 0.100 |
Why?
|
| Comorbidity | 1 | 2017 | 1497 | 0.100 |
Why?
|
| Communication | 3 | 2023 | 514 | 0.100 |
Why?
|
| Device Removal | 1 | 2013 | 222 | 0.090 |
Why?
|
| Telemedicine | 1 | 2017 | 426 | 0.090 |
Why?
|
| Fibrinolysis | 2 | 2021 | 38 | 0.090 |
Why?
|
| Silicon | 1 | 2010 | 12 | 0.090 |
Why?
|
| HIV Infections | 2 | 2013 | 1858 | 0.090 |
Why?
|
| Alkynes | 1 | 2010 | 26 | 0.090 |
Why?
|
| Phenazines | 1 | 2010 | 8 | 0.090 |
Why?
|
| Gentian Violet | 1 | 2010 | 8 | 0.090 |
Why?
|
| DNA, Ribosomal | 1 | 2010 | 54 | 0.090 |
Why?
|
| Patient Safety | 1 | 2015 | 397 | 0.090 |
Why?
|
| Anticoagulants | 3 | 2021 | 580 | 0.090 |
Why?
|
| Feasibility Studies | 2 | 2025 | 754 | 0.090 |
Why?
|
| Education, Medical | 1 | 2014 | 289 | 0.090 |
Why?
|
| Vancomycin | 1 | 2012 | 218 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2013 | 469 | 0.080 |
Why?
|
| Microscopy | 1 | 2010 | 117 | 0.080 |
Why?
|
| Polyamines | 1 | 2009 | 26 | 0.080 |
Why?
|
| Thrombolytic Therapy | 2 | 2021 | 204 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2010 | 401 | 0.080 |
Why?
|
| Silicones | 1 | 2008 | 33 | 0.080 |
Why?
|
| Operon | 1 | 2008 | 52 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2020 | 3020 | 0.080 |
Why?
|
| Polyethylene Glycols | 1 | 2009 | 221 | 0.070 |
Why?
|
| Phylogeny | 1 | 2010 | 694 | 0.070 |
Why?
|
| Hypertension | 1 | 2016 | 1284 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2025 | 2019 | 0.070 |
Why?
|
| Transplant Recipients | 2 | 2019 | 209 | 0.070 |
Why?
|
| Plasmids | 1 | 2008 | 513 | 0.070 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2011 | 439 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2021 | 998 | 0.070 |
Why?
|
| Equipment Contamination | 1 | 2007 | 38 | 0.070 |
Why?
|
| Leadership | 2 | 2020 | 226 | 0.070 |
Why?
|
| Immunity, Cellular | 1 | 2007 | 202 | 0.060 |
Why?
|
| Patient Readmission | 2 | 2021 | 367 | 0.060 |
Why?
|
| Drug Combinations | 2 | 2007 | 268 | 0.060 |
Why?
|
| Age Factors | 2 | 2019 | 2811 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 3867 | 0.060 |
Why?
|
| Pharyngitis | 1 | 2024 | 31 | 0.060 |
Why?
|
| Prescription Drug Overuse | 1 | 2024 | 3 | 0.060 |
Why?
|
| Common Cold | 1 | 2024 | 24 | 0.060 |
Why?
|
| Trauma Severity Indices | 1 | 2004 | 87 | 0.060 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2004 | 111 | 0.060 |
Why?
|
| Silver Sulfadiazine | 1 | 2004 | 9 | 0.060 |
Why?
|
| ROC Curve | 1 | 2006 | 558 | 0.060 |
Why?
|
| Injections, Intramuscular | 1 | 2004 | 191 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 1754 | 0.060 |
Why?
|
| Drug Resistance, Multiple | 1 | 2024 | 49 | 0.060 |
Why?
|
| Antibody Formation | 1 | 2004 | 256 | 0.060 |
Why?
|
| Vaccines, Inactivated | 1 | 2004 | 144 | 0.060 |
Why?
|
| Mice | 4 | 2022 | 17560 | 0.050 |
Why?
|
| Influenza A virus | 1 | 2004 | 138 | 0.050 |
Why?
|
| Providencia | 1 | 2003 | 3 | 0.050 |
Why?
|
| Catheterization, Central Venous | 2 | 2020 | 132 | 0.050 |
Why?
|
| Child | 4 | 2019 | 24256 | 0.050 |
Why?
|
| Pharmacists | 1 | 2023 | 83 | 0.050 |
Why?
|
| Diarrhea | 1 | 2024 | 315 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2024 | 435 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2023 | 280 | 0.050 |
Why?
|
| Animals | 5 | 2022 | 33857 | 0.050 |
Why?
|
| Intention | 2 | 2013 | 91 | 0.050 |
Why?
|
| Candidiasis | 1 | 2003 | 129 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2024 | 539 | 0.050 |
Why?
|
| Opportunistic Infections | 1 | 2002 | 78 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2008 | 844 | 0.050 |
Why?
|
| Genetic Fitness | 1 | 2021 | 34 | 0.050 |
Why?
|
| Medication Reconciliation | 1 | 2021 | 15 | 0.050 |
Why?
|
| Adaptation, Biological | 1 | 2021 | 33 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2022 | 202 | 0.050 |
Why?
|
| Pericardial Effusion | 1 | 2001 | 64 | 0.050 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2021 | 53 | 0.050 |
Why?
|
| beta-Lactamases | 1 | 2023 | 192 | 0.050 |
Why?
|
| Drug Antagonism | 1 | 2020 | 13 | 0.040 |
Why?
|
| Symbiosis | 1 | 2021 | 65 | 0.040 |
Why?
|
| Reflex | 1 | 2020 | 52 | 0.040 |
Why?
|
| Catholicism | 1 | 2020 | 5 | 0.040 |
Why?
|
| Hospitals, Religious | 1 | 2020 | 5 | 0.040 |
Why?
|
| Coronavirus | 1 | 2020 | 24 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2002 | 967 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2020 | 239 | 0.040 |
Why?
|
| Professional-Patient Relations | 1 | 2020 | 82 | 0.040 |
Why?
|
| Virulence Factors | 1 | 2021 | 172 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 726 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 147 | 0.040 |
Why?
|
| Models, Organizational | 1 | 2019 | 40 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2021 | 287 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2022 | 767 | 0.040 |
Why?
|
| Syndrome | 1 | 2002 | 1116 | 0.040 |
Why?
|
| Vaccination | 1 | 2004 | 947 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2021 | 294 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 263 | 0.040 |
Why?
|
| Quadriplegia | 1 | 2019 | 34 | 0.040 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2020 | 194 | 0.040 |
Why?
|
| Paraplegia | 1 | 2019 | 91 | 0.040 |
Why?
|
| Interinstitutional Relations | 1 | 2018 | 19 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2019 | 371 | 0.040 |
Why?
|
| Organoids | 1 | 2021 | 277 | 0.040 |
Why?
|
| Bacterial Load | 1 | 2018 | 29 | 0.040 |
Why?
|
| Colorectal Surgery | 1 | 2017 | 9 | 0.040 |
Why?
|
| Wound Healing | 1 | 2021 | 452 | 0.040 |
Why?
|
| Biosynthetic Pathways | 1 | 2017 | 25 | 0.040 |
Why?
|
| Colostomy | 1 | 2017 | 26 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2017 | 100 | 0.040 |
Why?
|
| Bacterial Translocation | 1 | 2017 | 24 | 0.040 |
Why?
|
| Colectomy | 1 | 2017 | 75 | 0.030 |
Why?
|
| Marfan Syndrome | 1 | 2019 | 137 | 0.030 |
Why?
|
| Virulence | 1 | 2017 | 261 | 0.030 |
Why?
|
| Practice Management, Medical | 1 | 2016 | 12 | 0.030 |
Why?
|
| Nursing Staff | 1 | 2016 | 13 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 4298 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 216 | 0.030 |
Why?
|
| Preventive Health Services | 1 | 2017 | 58 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 285 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2020 | 482 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2018 | 772 | 0.030 |
Why?
|
| Focus Groups | 1 | 2017 | 201 | 0.030 |
Why?
|
| Genome, Viral | 1 | 2017 | 170 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2017 | 153 | 0.030 |
Why?
|
| Vocabulary, Controlled | 1 | 2015 | 13 | 0.030 |
Why?
|
| Utah | 1 | 2015 | 45 | 0.030 |
Why?
|
| Biomarkers | 1 | 2025 | 2953 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 299 | 0.030 |
Why?
|
| Cryoelectron Microscopy | 1 | 2017 | 212 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2015 | 86 | 0.030 |
Why?
|
| Thrombosis | 1 | 2020 | 518 | 0.030 |
Why?
|
| Pneumonia | 1 | 2019 | 325 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 652 | 0.030 |
Why?
|
| Escherichia coli Proteins | 1 | 2017 | 303 | 0.030 |
Why?
|
| Iron | 1 | 2017 | 262 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 295 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2017 | 1070 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2019 | 1013 | 0.030 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 553 | 0.030 |
Why?
|
| Machine Learning | 1 | 2015 | 220 | 0.030 |
Why?
|
| Health Policy | 1 | 2015 | 213 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 1099 | 0.030 |
Why?
|
| Base Sequence | 1 | 2017 | 3091 | 0.030 |
Why?
|
| Logistic Models | 1 | 2016 | 1801 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2012 | 229 | 0.020 |
Why?
|
| Alkylation | 1 | 2010 | 10 | 0.020 |
Why?
|
| Microscopy, Atomic Force | 1 | 2010 | 13 | 0.020 |
Why?
|
| Infant | 1 | 2006 | 12376 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3053 | 0.020 |
Why?
|
| Obesity | 1 | 2022 | 2235 | 0.020 |
Why?
|
| Aging | 1 | 2017 | 1185 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2006 | 13918 | 0.020 |
Why?
|
| Biosensing Techniques | 1 | 2010 | 49 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2013 | 306 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 232 | 0.020 |
Why?
|
| Self Report | 1 | 2013 | 517 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2010 | 284 | 0.020 |
Why?
|
| Dendrimers | 1 | 2009 | 5 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 59 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2022 | 8114 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 427 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5056 | 0.020 |
Why?
|
| Cell Death | 1 | 2009 | 240 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 1080 | 0.020 |
Why?
|
| Pediatrics | 1 | 2017 | 1141 | 0.020 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2008 | 76 | 0.020 |
Why?
|
| Epithelium, Corneal | 1 | 2009 | 172 | 0.020 |
Why?
|
| Cell Survival | 1 | 2009 | 806 | 0.020 |
Why?
|
| Staphylococcus epidermidis | 1 | 2007 | 41 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2009 | 901 | 0.010 |
Why?
|
| Cell Line | 1 | 2009 | 2772 | 0.010 |
Why?
|